Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.
2.

Differentiation of pancreatic ductal adenocarcinoma from chronic pancreatitis by PAM4 immunohistochemistry.

Shi C, Merchant N, Newsome G, Goldenberg DM, Gold DV.

Arch Pathol Lab Med. 2014 Feb;138(2):220-8. doi: 10.5858/arpa.2013-0056-OA.

3.
4.

Diagnostic and therapeutic implications of a novel immunohistochemical panel detecting duodenal mucosal invasion by pancreatic ductal adenocarcinoma.

Sopha SC, Gopal P, Merchant NB, Revetta FL, Gold DV, Washington K, Shi C.

Int J Clin Exp Pathol. 2013 Oct 15;6(11):2476-86. eCollection 2013.

5.

Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers.

Govindan SV, Cardillo TM, Sharkey RM, Tat F, Gold DV, Goldenberg DM.

Mol Cancer Ther. 2013 Jun;12(6):968-78. doi: 10.1158/1535-7163.MCT-12-1170. Epub 2013 Feb 20.

6.

Horizontal transmission of malignancy: in-vivo fusion of human lymphomas with hamster stroma produces tumors retaining human genes and lymphoid pathology.

Goldenberg DM, Gold DV, Loo M, Liu D, Chang CH, Jaffe ES.

PLoS One. 2013;8(2):e55324. doi: 10.1371/journal.pone.0055324. Epub 2013 Feb 6.

7.

Prevention of acute graft-versus-host disease in a xenogeneic SCID mouse model by the humanized anti-CD74 antagonistic antibody milatuzumab.

Chen X, Chang CH, Stein R, Cardillo TM, Gold DV, Goldenberg DM.

Biol Blood Marrow Transplant. 2013 Jan;19(1):28-39. doi: 10.1016/j.bbmt.2012.09.015. Epub 2012 Sep 28.

8.

PAM4 enzyme immunoassay alone and in combination with CA 19-9 for the detection of pancreatic adenocarcinoma.

Gold DV, Gaedcke J, Ghadimi BM, Goggins M, Hruban RH, Liu M, Newsome G, Goldenberg DM.

Cancer. 2013 Feb 1;119(3):522-8. doi: 10.1002/cncr.27762. Epub 2012 Aug 16.

9.

Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial.

Ocean AJ, Pennington KL, Guarino MJ, Sheikh A, Bekaii-Saab T, Serafini AN, Lee D, Sung MW, Gulec SA, Goldsmith SJ, Manzone T, Holt M, O'Neil BH, Hall N, Montero AJ, Kauh J, Gold DV, Horne H, Wegener WA, Goldenberg DM.

Cancer. 2012 Nov 15;118(22):5497-506. doi: 10.1002/cncr.27592. Epub 2012 May 8.

10.

Evaluation of a non-viral vaccine in smallpox-vaccinated individuals and immunized HLA-transgenic mice.

Taylor AP, Makabi-Panzu B, Chen X, Gold DV, Goldenberg DM.

Hum Immunol. 2012 Jun;73(6):612-9. doi: 10.1016/j.humimm.2012.03.009. Epub 2012 Apr 12.

PMID:
22504409
11.

Horizontal transmission and retention of malignancy, as well as functional human genes, after spontaneous fusion of human glioblastoma and hamster host cells in vivo.

Goldenberg DM, Zagzag D, Heselmeyer-Haddad KM, Berroa Garcia LY, Ried T, Loo M, Chang CH, Gold DV.

Int J Cancer. 2012 Jul 1;131(1):49-58. doi: 10.1002/ijc.26327. Epub 2011 Aug 30.

12.

Treatment of advanced pancreatic carcinoma with 90Y-Clivatuzumab Tetraxetan: a phase I single-dose escalation trial.

Gulec SA, Cohen SJ, Pennington KL, Zuckier LS, Hauke RJ, Horne H, Wegener WA, Teoh N, Gold DV, Sharkey RM, Goldenberg DM.

Clin Cancer Res. 2011 Jun 15;17(12):4091-100. doi: 10.1158/1078-0432.CCR-10-2579. Epub 2011 Apr 28.

13.

Enhanced expression of CD74 in gastrointestinal cancers and benign tissues.

Gold DV, Stein R, Burton J, Goldenberg DM.

Int J Clin Exp Pathol. 2010 Nov 23;4(1):1-12.

14.

Detection of early-stage pancreatic adenocarcinoma.

Gold DV, Goggins M, Modrak DE, Newsome G, Liu M, Shi C, Hruban RH, Goldenberg DM.

Cancer Epidemiol Biomarkers Prev. 2010 Nov;19(11):2786-94. doi: 10.1158/1055-9965.EPI-10-0667. Epub 2010 Sep 1.

15.

Pretargeted radioimmunotherapy of pancreatic cancer xenografts: TF10-90Y-IMP-288 alone and combined with gemcitabine.

Karacay H, Sharkey RM, Gold DV, Ragland DR, McBride WJ, Rossi EA, Chang CH, Goldenberg DM.

J Nucl Med. 2009 Dec;50(12):2008-16. doi: 10.2967/jnumed.109.067686.

16.

Ceramide regulates gemcitabine-induced senescence and apoptosis in human pancreatic cancer cell lines.

Modrak DE, Leon E, Goldenberg DM, Gold DV.

Mol Cancer Res. 2009 Jun;7(6):890-6. doi: 10.1158/1541-7786.MCR-08-0457. Epub 2009 Jun 16.

17.

A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma.

Gold DV, Goldenberg DM, Karacay H, Rossi EA, Chang CH, Cardillo TM, McBride WJ, Sharkey RM.

Cancer Res. 2008 Jun 15;68(12):4819-26. doi: 10.1158/0008-5472.CAN-08-0232.

18.

PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma.

Gold DV, Karanjawala Z, Modrak DE, Goldenberg DM, Hruban RH.

Clin Cancer Res. 2007 Dec 15;13(24):7380-7.

19.

Sphingolipid targets in cancer therapy.

Modrak DE, Gold DV, Goldenberg DM.

Mol Cancer Ther. 2006 Feb;5(2):200-8. Review.

20.

New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis.

Gold DV, Modrak DE, Ying Z, Cardillo TM, Sharkey RM, Goldenberg DM.

J Clin Oncol. 2006 Jan 10;24(2):252-8. Epub 2005 Dec 12.

PMID:
16344318
21.

Identification of a Mu-9 (anti-colon-specific antigen-p)-reactive peptide having homology to CA125 (MUC16).

Modrak DE, Karacay H, Cardillo TM, Newsome G, Goldenberg DM, Gold DV.

Int J Oncol. 2005 Jun;26(6):1591-6.

PMID:
15870874
22.

Synergistic interaction between sphingomyelin and gemcitabine potentiates ceramide-mediated apoptosis in pancreatic cancer.

Modrak DE, Cardillo TM, Newsome GA, Goldenberg DM, Gold DV.

Cancer Res. 2004 Nov 15;64(22):8405-10.

23.

CD74 is expressed by multiple myeloma and is a promising target for therapy.

Burton JD, Ely S, Reddy PK, Stein R, Gold DV, Cardillo TM, Goldenberg DM.

Clin Cancer Res. 2004 Oct 1;10(19):6606-11.

24.

Improved targeting of pancreatic cancer: experimental studies of a new bispecific antibody, pretargeting enhancement system for immunoscintigraphy.

Cardillo TM, Karacay H, Goldenberg DM, Yeldell D, Chang CH, Modrak DE, Sharkey RM, Gold DV.

Clin Cancer Res. 2004 May 15;10(10):3552-61.

26.

Low-dose radioimmunotherapy ((90)Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer.

Gold DV, Schutsky K, Modrak D, Cardillo TM.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3929S-37S.

27.

Colonic tumor CEA, CSAp and MUC-1 expression following radioimmunotherapy or chemotherapy.

Modrak DE, Gold DV, Goldenberg DM, Blumenthal RD.

Tumour Biol. 2003 Jan-Feb;24(1):32-9.

PMID:
12743424
28.

Interferon-gamma upregulates MUC1 expression in haematopoietic and epithelial cancer cell lines, an effect associated with MUC1 mRNA induction.

Reddy PK, Gold DV, Cardillo TM, Goldenberg DM, Li H, Burton JD.

Eur J Cancer. 2003 Feb;39(3):397-404.

PMID:
12565994
29.

Monoclonal antibody G47 engineered to be reactive with colorectal tumor mucin.

Gold DV, Cardillo TM.

Hybrid Hybridomics. 2001;20(5-6):343-50.

PMID:
11839252
30.

Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer.

Cardillo TM, Blumenthal R, Ying Z, Gold DV.

Int J Cancer. 2002 Jan 20;97(3):386-92.

31.
32.

Localization of pancreatic cancer with radiolabeled monoclonal antibody PAM4.

Gold DV, Cardillo T, Goldenberg DM, Sharkey RM.

Crit Rev Oncol Hematol. 2001 Jul-Aug;39(1-2):147-54.

PMID:
11418312
33.

Epithelial mucin-1 (MUC1) expression and MA5 anti-MUC1 monoclonal antibody targeting in multiple myeloma.

Burton J, Mishina D, Cardillo T, Lew K, Rubin A, Goldenberg DM, Gold DV.

Clin Cancer Res. 1999 Oct;5(10 Suppl):3065s-3072s.

PMID:
10541345
34.

Co-secretion of two distinct kappa light chains by the mu-9 hybridoma.

Krishnan IS, Hansen HJ, Gold DV, Goldenberg DM, Leung SO.

Hybridoma. 1999 Aug;18(4):325-33.

PMID:
10571262
35.

Radioimmunotherapy of experimental pancreatic cancer with 131I-labeled monoclonal antibody PAM4.

Gold DV, Cardillo T, Vardi Y, Blumenthal R.

Int J Cancer. 1997 May 16;71(4):660-7.

36.

Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors.

Behr TM, Sharkey RM, Juweid MI, Dunn RM, Ying Z, Zhang CH, Siegel JA, Gold DV, Goldenberg DM.

Cancer Res. 1996 Apr 15;56(8):1805-16.

37.

Initial tumor targeting, biodistribution, and pharmacokinetic evaluation of the monoclonal antibody PAM4 in patients with pancreatic cancer.

Mariani G, Molea N, Bacciardi D, Boggi U, Fornaciari G, Campani D, Salvadori PA, Giulianotti PC, Mosca F, Gold DV, et al.

Cancer Res. 1995 Dec 1;55(23 Suppl):5911s-5915s.

38.

Initial studies of monoclonal antibody PAM4 targeting to xenografted orthotopic pancreatic cancer.

Alisauskus R, Wong GY, Gold DV.

Cancer Res. 1995 Dec 1;55(23 Suppl):5743s-5748s.

39.

Targeting of xenografted pancreatic cancer with a new monoclonal antibody, PAM4.

Gold DV, Alisauskas R, Sharkey RM.

Cancer Res. 1995 Mar 1;55(5):1105-10.

40.

Characterization of monoclonal antibody PAM4 reactive with a pancreatic cancer mucin.

Gold DV, Lew K, Maliniak R, Hernandez M, Cardillo T.

Int J Cancer. 1994 Apr 15;57(2):204-10.

PMID:
7512537
41.

Microheterogeneity of a purified IgG1 due to asymmetric Fab glycosylation.

Grebenau RC, Goldenberg DM, Chang CH, Koch GA, Gold DV, Kunz A, Hansen HJ.

Mol Immunol. 1992 Jun;29(6):751-8.

PMID:
1603094
42.

Murine monoclonal antibodies to colon-specific antigen p.

Gold DV, Nocera MA, Stephens R, Goldenberg DM.

Cancer Res. 1990 Oct 1;50(19):6405-9.

43.

Comparison of tumor targeting in nude mice by murine monoclonal antibodies directed against different human colorectal cancer antigens.

Sharkey RM, Gold DV, Aninipot R, Vagg R, Ballance C, Newman ES, Ostella F, Hansen HJ, Goldenberg DM.

Cancer Res. 1990 Feb 1;50(3 Suppl):828s-834s.

44.
45.

Studies on the structure of the organ-specific determinant of human colonic mucin.

Gold DV, Shochat D.

Mol Immunol. 1989 Aug;26(8):769-77.

PMID:
2478876
46.
47.

Organ specific antigens of the human gastrointestinal tract.

Gold DV, Ishizaki G, Shochat D.

Mol Immunol. 1986 Oct;23(10):1031-7.

PMID:
2432407
48.

Growth inhibition of a rat colon tumor by L-canavanine.

Thomas DA, Rosenthal GA, Gold DV, Dickey K.

Cancer Res. 1986 Jun;46(6):2898-903.

49.

Characterization of two metastatic subpopulations originating from a single human colon carcinoma.

Spremulli EN, Scott C, Campbell DE, Libbey NP, Shochat D, Gold DV, Dexter DL.

Cancer Res. 1983 Aug;43(8):3828-35.

50.

Differential expression of tumor-associated antigens in human colon carcinomas xenografted into nude mice.

Gold DV, Shochat D, Primus FJ, Dexter DL, Calabresi P, Goldenberg DM.

J Natl Cancer Inst. 1983 Jul;71(1):117-24.

PMID:
6575198

Supplemental Content

Support Center